ORIC Company Profile and Key Details

Q: Who are the executives of ORIC?

Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Charles L. Sawyers B.A., BA, M.D., Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Pratik S. Multani M.D., M.S.Chief Medical OfficerMr. Dominic G. Piscitelli CPA, CPA, M.B.A.Chief Financial OfficerDr. Jacob M. Chacko M.B.A., M.D.Pres, Chief Executive Officer & DirectorDr. Lori Sickels Friedman Ph.D.Chief Scientific OfficerDr. Christian V. Kuhlen Esq., J.D., M.D.Gen. CounselDr. Edna Chow ManevalSenior Vice President of Clinical Devel.Mr. Daniel IazzettiVice President & Head of People

NASDAQ : ORIC

ORIC Pharmaceuticals

$11.05

0.3+2.79%

Open: 12:50 PM

64.51

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ORIC Pharmaceuticals, Inc. (ORIC) stock surged +2.79%, trading at $11.05 on NASDAQ, up from the previous close of $10.75. The stock opened at $10.72, fluctuating between $10.63 and $11.15 in the recent session.

Stock Snapshot

10.75

Prev. Close

1.11B

Market Cap

10.625

Day Low

-7.52

P/E Ratio

-1.47

EPS (TTM)

-1.51

Cash Flow per Share

10.72

Open

100.36M

Number of Shares

11.15

Day High

47.05%

Free Float in %

3.9

Book Value

413.57K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 17, 2026	10.42	10.98	10.30	10.75	1.75M
Apr 16, 2026	10.22	10.49	10.10	10.23	1.36M
Apr 14, 2026	10.45	10.85	10.40	10.53	974.85K
Apr 13, 2026	10.08	10.93	10.03	10.40	1.52M
Apr 10, 2026	10.38	10.48	9.98	10.15	2.1M
Apr 09, 2026	8.90	10.41	8.90	10.38	2.38M
Apr 08, 2026	8.98	9.23	8.76	9.05	1.69M
Apr 07, 2026	9.00	9.03	8.68	8.87	1.44M
Apr 06, 2026	8.91	9.53	8.73	8.91	2.44M
Apr 02, 2026	7.25	8.97	7.23	8.89	7.26M
Apr 01, 2026	10.25	10.80	7.37	7.48	15.5M
Mar 31, 2026	12.64	13.04	12.23	12.67	1.71M
Mar 30, 2026	12.00	12.40	11.71	12.19	1.4M
Mar 27, 2026	12.13	12.74	11.76	12.06	1.34M
Mar 25, 2026	11.30	11.99	11.29	11.70	1.04M
Mar 24, 2026	10.96	11.27	10.73	11.10	990.75K
Mar 23, 2026	11.22	11.62	10.59	11.13	1.5M
Mar 20, 2026	11.07	11.38	10.77	11.16	3.7M
Mar 19, 2026	11.21	11.36	10.64	11.10	1.25M
Mar 18, 2026	11.93	11.93	10.85	10.86	1.25M

Contact Details

South San Francisco, CA 94080

United States

https://www.oricpharma.com 650 388 5600

About Company

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Stock Peers

ARGX

20.69+2.50%

argenx SE$849.04 REGN

4.57+0.61%

Regeneron Pharmaceuticals, Inc.$750.57 UTHR

7.87+1.36%

United Therapeutics Corporation$588.38 MDGL

7.26+1.38%

Madrigal Pharmaceuticals, Inc.$532.02 VRTX

5.55+1.27%

Vertex Pharmaceuticals Incorporated$441.20 PRAX

22.11+6.90%

Praxis Precision Medicines, Inc.$342.50 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-10.47-3.27%

Alnylam Pharmaceuticals, Inc.$309.66 KRYS

10.15+3.84%

Krystal Biotech, Inc.$274.21 ASND

1.53+0.63%

Ascendis Pharma A/S$244.48

Company Overview

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) closed at $11.05 USD, gaining $0.30 (2.79%) from the previous close of $10.75. The stock is currently mid-range between its 52-week high and low $4.52 and $14.93. With a market capitalization of about $1.11 billion, ORIC Pharmaceuticals, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 1.94 million shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, ORIC Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jacob Chacko, the company employs approximately 122 people and listed since April 24, 2020. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.

Technical Performance

ORIC has shown mixed momentum, gaining 26.99% over the past week and -9.08% over the past quarter, though year-to-date performance is up 42.05%. Short-term trend indicators are mixed aligned (SMA20 22.03%, SMA50 32.36%, SMA200 29.02%). The stock’s 14-day RSI is 70.8 (overbought), while the ATR of 0.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.58% below its high and over 246.59% above its low. Average 10-day trading volume of 1.54 million shares is below the 3-month average of 1.95 million, indicating normal recent market interest.

Valuation Metrics

ORIC Pharmaceuticals, Inc. trades at a P/E ratio of -7.29, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.46 suggesting the stock is closer to book value. The P/FCF stands at -9.63, also below market averages.

Dividend & Fair Value

ORIC Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.39. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

ORIC Pharmaceuticals, Inc. generated EPS of -$1.51 over the past year. Five-year average earnings growth is 15.18%. Wall Street analysts project EPS growth of -3.85% annually over the next five years. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.34. Next year's EPS is expected at -$3.68. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $15.00. The high target offers 132.56% upside. The low target suggests 39.53% downside. The mean target is $20.05. This offers 86.51% upside. ORIC Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -19.51%. The prior quarter beat by 2.17%. Over the last six quarters, Apple has recorded several small beats. These include 7.14% in August 12, 2024.

Shareholding & Insider Activity

ORIC Pharmaceuticals, Inc. has 97.12 million shares outstanding. The public float is 53.43 million shares, elevated short interest at 8.05% of float. This equals 6.76 million shares. The short ratio is 5.99 days. Institutional investors hold 106.6% of the float. Insiders own 6.94%. GORDON CARL L holds 2.21 million shares, ORBIMED ADVISORS LLC has 2.21 million shares and Topspin Fund L.P. has 1.10 million shares. Over the past six months, insider transactions show net selling. They sold 110.31 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, ORIC Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -39.54% and ROE at -44.94%.
On valuation metrics, ORIC Pharmaceuticals trades at a P/E of -7.29, P/S of 0.00 and P/B of 2.46. The current ratio is 14.13 and quick ratio is 14.13. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -4361.75 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of -9.63.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ORIC Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $1.03M (margin 0.00%). Operating income was - $110.78M (margin 0.0%). Net income was- $100.70M (EPS - $1.96).
The company ended the quarter with $208.19M in cash and short-term investments, a total debt of $10.21M, and net debt of - $13.17M. Total assets were $254.69M, with equity of $224.09M. Financials further reflected weakness, with operating cash flow of - $85.92M, free cash flow of - $86.76M, and capital expenditures of - $849.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that ORIC Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.33%, with price expected at $9.64 by May 01, 2026, within a range of $8.48 to $10.72 3-Month Outlook: Projected rise of 239.53%, reaching $36.50 by July 16, 2026, with a range of $36.02 to $37.27. 1-Year Outlook: Projected gain of 109.95%, with price at $22.57 by April 16, 2027, within a range of $16.82 to $32.04.

Key Takeaways

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) shares are up 42.05% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ORIC Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -7.29. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.21, suggesting 97.3% upside. Our AI forecast model points to short-term weakness (-10.33% over two weeks), a medium-term rise (239.53% over three months), and a longer-term gain (109.95% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ORIC Pharmaceuticals, Inc. (ORIC) stock price?

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) stock price is $11.05 in the last trading session. During the trading session, ORIC stock reached the peak price of $11.15 while $10.63 was the lowest point it dropped to. The percentage change in ORIC stock occurred in the recent session was 2.79% while the dollar amount for the price change in ORIC stock was $0.30.

ORIC's industry and sector of operation?

The NASDAQ listed ORIC is part of Biotechnology industry that operates in the broader Healthcare sector. ORIC Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ORIC?

Dr. Scott W. Lowe Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Charles L. Sawyers B.A., BA, M.D., Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Pratik S. Multani M.D., M.S.
Chief Medical Officer
Mr. Dominic G. Piscitelli CPA, CPA, M.B.A.
Chief Financial Officer
Dr. Jacob M. Chacko M.B.A., M.D.
Pres, Chief Executive Officer & Director
Dr. Lori Sickels Friedman Ph.D.
Chief Scientific Officer
Dr. Christian V. Kuhlen Esq., J.D., M.D.
Gen. Counsel
Dr. Edna Chow Maneval
Senior Vice President of Clinical Devel.
Mr. Daniel Iazzetti
Vice President & Head of People

How ORIC did perform over past 52-week?

ORIC's closing price is 137.83% higher than its 52-week low of $4.52 where as its distance from 52-week high of $14.93 is -28%.

How many employees does ORIC have?

Number of ORIC employees currently stands at 122.

Link for ORIC official website?

Official Website of ORIC is: https://www.oricpharma.com

How do I contact ORIC?

ORIC could be contacted at phone 650 388 5600 and can also be accessed through its website. ORIC operates from 240 East Grand Avenue, South San Francisco, CA 94080, United States.

How many shares of ORIC are traded daily?

ORIC stock volume for the day was 413.57K shares. The average number of ORIC shares traded daily for last 3 months was 1.94M.

What is the market cap of ORIC currently?

The market value of ORIC currently stands at $1.11B with its latest stock price at $11.05 and 100.36M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	122
Beta	1.36
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ORIC Company Profile and Key Details

ORIC Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways